Currently, there are three major phase III clinical trials ongoing to study the role of anti-IL-33 agent tozorakimab in COPD patients (OBERON trial, NCT05166889; TITANIA trial, NCT05158387; PROSPERO trial, NCT05742802). Here, IL33 is linked to chronic obstructive pulmonary disease.